MarketCap
Facebook
X
Telegram
Moleculin Biotech Balance Sheet 2025-2011 | MBRX
Brief overview of Moleculin Biotech's assets and capital
The comparison uses five available annual reports from the 2021–2025 interval.
Assets declined from $84.1 million to $22.1 million, or -73.7%. The contraction calls for context such as disposals, restructuring or weaker operations.
Asset growth of -73.7% came with a +39.7% rise in liabilities. Financial leverage became more prominent.
Equity accounts for 67.8% of assets. Against the initial 93.9%, the capital position looks resilient.
Negative net debt of -$8.5 million means cash holdings are larger than debt obligations.
The cash reserve occupies 40.1% of the balance sheet, previously 84.3%. It is one marker of short-term resilience.
Retained earnings remain negative at -$206 million. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
Conclusion
Moleculin Biotech's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet Moleculin Biotech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-8.52 M | -3.8 M | -23 M | -42.8 M | -70.8 M | -14.9 M | -10.4 M | -7.13 M | -7.71 M | -4.71 M | 422 K | - | - | - | - |
Long Term Debt |
222 K | 358 K | 474 K | 335 K | 63 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
137 K | 120 K | 100 K | - | - | - | 103 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 8.35 M | 6.09 M | 1.44 M | 150 K | 87.5 K | - | - | - | - | - |
Total Current Liabilities |
6.85 M | 5.36 M | 6.82 M | 4.82 M | 3.62 M | 2.92 M | 3.57 M | 3.88 M | 2.22 M | 1.35 M | - | - | - | - | - |
Total Liabilities |
7.12 M | 5.72 M | 12.1 M | 5.23 M | 5.1 M | 11.3 M | 9.66 M | 5.31 M | 2.36 M | 1.43 M | 773 K | - | - | - | - |
Retained Earnings |
-206 M | -172 M | -132 M | -102 M | -72.8 M | -56.9 M | -39.6 M | -26.4 M | -14.5 M | -4.67 M | -748 K | - | - | - | - |
Total Assets |
22.1 M | 16.9 M | 38.2 M | 57.4 M | 84.1 M | 29 M | 25.2 M | 19.6 M | 19.5 M | 16.4 M | 28.1 K | - | - | - | - |
Cash and Cash Equivalents |
8.88 M | 4.28 M | 23.6 M | 43.1 M | 70.9 M | 15.2 M | 10.7 M | 7.13 M | 7.71 M | 5.01 M | 28.1 K | - | - | - | - |
Book Value |
15 M | 11.2 M | 26.1 M | 52.2 M | 79 M | 17.8 M | 15.6 M | 14.3 M | 17.1 M | 15 M | -745 K | - | - | - | - |
Total Shareholders Equity |
15 M | 11.2 M | 30.9 M | 52.2 M | 79 M | 17.8 M | 15.6 M | 14.3 M | 17.1 M | 15 M | -745 K | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Moleculin Biotech
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
185 K | 258 K | 292 K | 326 K | 358 K | 390 K | 420 K | - | 474 K | 496 K | 291 K | 308 K | 335 K | 365 K | 388 K | 50 K | 63 K | 75 K | 94 K | 127 K | 159 K | 159 K | 159 K | 159 K | 276 K | 276 K | 276 K | 276 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.18 M | 47.3 M | 28.8 M | 21 M | 5.72 M | 15.9 M | 7.87 M | - | 12.1 M | 4.38 M | 6.85 M | 5.38 M | 5.23 M | 6.96 M | 6.9 M | 6.14 M | 5.1 M | 7.44 M | 8.83 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | 9.66 M | 9.66 M | 9.66 M | 9.66 M | 5.31 M | 5.31 M | 5.31 M | 5.31 M | 2.36 M | 2.36 M | 2.36 M | 2.36 M | 1.43 M | 1.43 M | 1.43 M | 1.43 M | 773 K | 773 K | 773 K | 773 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-219 M | -222 M | -167 M | -160 M | -172 M | -151 M | -141 M | - | -132 M | -121 M | -116 M | -110 M | -102 M | -95.1 M | -86.5 M | -79.7 M | -72.8 M | -70 M | -65.6 M | -61.4 M | -56.9 M | -56.9 M | -56.9 M | -56.9 M | -39.6 M | -39.6 M | -39.6 M | -39.6 M | -26.4 M | -26.4 M | -26.4 M | -26.4 M | -14.5 M | -14.5 M | -14.5 M | -14.5 M | -4.68 M | -4.68 M | -4.68 M | -4.68 M | -748 K | -748 K | -748 K | -748 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
23.4 M | 20.4 M | 21.6 M | 21 M | 16.9 M | 23.4 M | 25.6 M | - | 38.2 M | 39.5 M | 47.1 M | 51.1 M | 57.4 M | 65.4 M | 73.3 M | 78.8 M | 84.1 M | 88.7 M | 93.5 M | 99.8 M | 29 M | 29 M | 29 M | 29 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | 19.6 M | 19.6 M | 19.6 M | 19.6 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 16.4 M | 16.4 M | 16.4 M | 16.4 M | 28.1 K | 28.1 K | 28.1 K | 28.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
10.3 M | 6.7 M | 7.56 M | 7.72 M | 4.28 M | 9.4 M | 10.8 M | 16.8 M | 23.6 M | 24.6 M | 32.2 M | 37.3 M | 43.1 M | 50.4 M | 58 M | 66.1 M | 70.9 M | 75.2 M | 79.5 M | 86.3 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 7.13 M | 7.13 M | 7.13 M | 7.13 M | 7.71 M | 7.71 M | 7.71 M | 7.71 M | 5.01 M | 5.01 M | 5.01 M | 5.01 M | 28 K | 28.1 K | 28.1 K | 28.1 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
15.2 M | -26.9 M | -7.16 M | 42 K | 11.2 M | 7.48 M | 17.7 M | - | 26.1 M | 35.1 M | 40.3 M | 45.7 M | 52.2 M | 58.4 M | 66.4 M | 72.7 M | 79 M | 81.3 M | 84.7 M | 88.5 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 15 M | 15 M | 15 M | 15 M | -745 K | -745 K | -745 K | -745 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
15.2 M | -26.9 M | -7.16 M | 42 K | 11.2 M | 17.4 M | 17.7 M | 21.6 M | 26.1 M | 35.1 M | 40.3 M | 45.7 M | 52.2 M | 58.4 M | 66.4 M | 72.7 M | 79 M | 81.3 M | 84.7 M | 88.5 M | 17.8 M | 17.8 M | 17.8 M | 17.8 M | 15.6 M | 15.6 M | 15.6 M | 15.6 M | 14.3 M | 14.3 M | 14.3 M | 14.3 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 15 M | 15 M | 15 M | 15 M | -745 K | -745 K | -745 K | -745 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Moleculin Biotech, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
